New breast cancer pill combo shows promise in Late-Stage trial
NCT ID NCT05909397
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests a new experimental drug, vepdegestrant, combined with palbociclib against the standard treatment (letrozole plus palbociclib) for people with advanced ER+/HER2- breast cancer that has not been treated before. The study aims to see if the new combination works better at stopping the cancer from growing. Participants take pills by mouth daily until the cancer worsens or side effects become too severe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Vepdegestrant (ARV-471) plus palbociclib
What this could lead to
If successful, this could offer a new first-line treatment option for people with advanced ER+/HER2- breast cancer, potentially delaying disease progression.
What could go wrong
This is an early-stage study lead-in before the main Phase 3, so results are preliminary. The new drug may not prove more effective than the current standard, and side effects like low white blood cell counts are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aichi Cancer Center Hospital
Nagoya, Aichi-ken, 464-8681, Japan
-
BRCR Global
Plantation, Florida, 33322, United States
-
BRCR Medical Center Inc
Plantation, Florida, 33322, United States
-
Barwon Health
Geelong, Victoria, 3220, Australia
-
Cancer Hospital Chinese Academy of Medical Science
Beijing, Beijing Municipality, 100021, China
-
Cancer Research SA
Adelaide, South Australia, 5000, Australia
-
Centro Gaucho Integrado De Oncologia, Hematologia, Ensino E Pesquisa
Porto Alegre, Rio Grande do Sul, 90110-270, Brazil
-
Centro de Pesquisa Clínica - Área Administrativa
Porto Alegre, Rio Grande do Sul, 90850-170, Brazil
-
Complejo Hospitalario de Jaén
Jaén, JAÉN, 23007, Spain
-
Debreceni Egyetem Klinikai Kozpont
Debrecen, 04032, Hungary
-
Fakultna nemocnica s poliklinikou J.A. Reimana Presov
Prešov, 080 01, Slovakia
-
Fondazione IRCCS San Gerardo dei Tintori
Monza, Lombardy, 20900, Italy
-
Hospital Clinico San Carlos
Madrid, 28040, Spain
-
Hospital Mae de Deus
Porto Alegre, Rio Grande do Sul, 90880-480, Brazil
-
Hospital Santa Rita de Cassia
Vitória, Espírito Santo, 29043-260, Brazil
-
Hospital Universitari Dexeus
Barcelona, Catalunya [cataluña], 08028, Spain
-
Hospital Universitario Virgen de la Victoria
Málaga, Málaga, 29010, Spain
-
Hospital Unviersitario Virgen Nieves
Granada, 18012, Spain
-
Hubei Cancer Hospital
Wuhan, Hubei, 430079, China
-
IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"
Meldola, Emilia-Romagna, 47014, Italy
-
Institut Català d'Oncologia (ICO) - Badalona
Badalona, Barcelona [barcelona], 08916, Spain
-
Istituto Nazionale Tumori IRCCS Fondazione Pascale
Naples, Campania, 80131, Italy
-
National Cancer Center Hospital
Chuo-ku, Tokyo, 104-0045, Japan
-
National Cancer Center Hospital East
Kashiwa, Chiba, 277-8577, Japan
-
Nemocnica na okraji mesta n o
Partizánske, 95801, Slovakia
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
-
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, 710061, China
-
Tumor Zentrum Aarau
Aarau, Canton of Aargau, 5000, Switzerland
-
Virginia Oncology Associates
Norfolk, Virginia, 23502, United States